Nirsevimab significantly protected infants against RSV disease in Phase III MELODY trial
Nirsevimab showed 74.5% efficacy against medically attended lower respiratory tract infections caused by RSV in healthy infants. Nirsevimab is the first potential immunisation for all infants to demonstrate sustained protection across the entire RSV season with a single dose. MELODY and MEDLEY trial results were published in the New England Journal of Medicine.Detailed results from the positive MELODY Phase III trial showed a single dose of AstraZeneca and Sanofi’s nirsevimab met the primary efficacy endpoint reducing the incidence of medically attended lower respiratory tract